These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product. Schnuchel A; Radcke C; Theobald L; Doeding S PLoS One; 2023; 18(6):e0285948. PubMed ID: 37319282 [TBL] [Abstract][Full Text] [Related]
5. Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines. Saeed H; Hemida A; El-Nikhely N; Abdel-Fattah M; Shalaby M; Hussein A; Eldoksh A; Ataya F; Aly N; Labrou N; Nematalla H Int J Biol Macromol; 2020 Aug; 156():812-828. PubMed ID: 32311402 [TBL] [Abstract][Full Text] [Related]
6. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase. Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072 [TBL] [Abstract][Full Text] [Related]
7. Bacillus sonorensis L. Asparaginase: Cloning, Expression in E. coli and Characterization. Aly N; El-Ahwany A; Ataya FS; Saeed H Protein J; 2020 Dec; 39(6):717-729. PubMed ID: 33106988 [TBL] [Abstract][Full Text] [Related]
8. L-Asparaginase from Erwinia Chrysanthemi 3937: cloning, expression and characterization. Kotzia GA; Labrou NE J Biotechnol; 2007 Jan; 127(4):657-69. PubMed ID: 16984804 [TBL] [Abstract][Full Text] [Related]
9. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia. Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829 [TBL] [Abstract][Full Text] [Related]
10. Polyoxazoline-Conjugated l-Asparaginase: An Antibody-Production-Free Therapeutic Agent for Acute Lymphoblastic Leukemia. Yamada T; Ishimaru M; Shoji T; Tomiyasu H; Tochinai R; Taguchi K; Komatsu T ACS Appl Bio Mater; 2023 Dec; 6(12):5789-5797. PubMed ID: 38047730 [TBL] [Abstract][Full Text] [Related]
11. Microbial L-asparaginase as a promising enzyme for treatment of various cancers. Darvishi F; Jahanafrooz Z; Mokhtarzadeh A Appl Microbiol Biotechnol; 2022 Sep; 106(17):5335-5347. PubMed ID: 35871694 [TBL] [Abstract][Full Text] [Related]
12. Beta-aspartylpeptides as substrates of L-asparaginases from Escherichia coli and Erwinia chrysanthemi. Kelo E; Noronkoski T; Stoineva IB; Petkov DD; Mononen I FEBS Lett; 2002 Sep; 528(1-3):130-2. PubMed ID: 12297292 [TBL] [Abstract][Full Text] [Related]
13. Enzyme Engineering Strategies for the Bioenhancement of L-Asparaginase Used as a Biopharmaceutical. Miranda J; Lefin N; Beltran JF; Belén LH; Tsipa A; Farias JG; Zamorano M BioDrugs; 2023 Nov; 37(6):793-811. PubMed ID: 37698749 [TBL] [Abstract][Full Text] [Related]
14. In Silico Design of a Chimeric Humanized L-asparaginase. Pedroso A; Herrera Belén L; Beltrán JF; Castillo RL; Pessoa A; Pedroso E; Farías JG Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108713 [TBL] [Abstract][Full Text] [Related]
15. Expression, purification, and characterization of asparaginase II from Saccharomyces cerevisiae in Escherichia coli. Lopes W; Santos BAFD; Sampaio ALF; Gregório Alves Fontão AP; Nascimento HJ; Jurgilas PB; Torres FAG; Bon EPDS; Almeida RV; Ferrara MA Protein Expr Purif; 2019 Jul; 159():21-26. PubMed ID: 30836141 [TBL] [Abstract][Full Text] [Related]